Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests

Dec 04, 2017

|

NEW YORK (GenomeWeb) – Biocartis announced today that it has signed a companion diagnostic development agreement with Amgen for its Idylla RAS biomarker tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests

To read the full story....

Breaking News

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

What's Popular?

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Illumina to Acquire Grail for $8B in Cash and Stock

Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships